

## Homeopathic Treatment as an Add-On Therapy May Improve Quality of Life and Prolong Survival in Patients with Non-Small Cell Lung Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Three-Arm, Multicenter Study

MICHAEL FRASS, PETER LECHLEITNER, CHRISTA GRÜNDLING, CLAUDIA PIRKER, ERWIN GRASMUK-SIEGL, JULIAN DOMAYER, MAXIMILIAN HOCHMAIR, KATHARINA GAERTNER, CORNELIA DUSCHECK, ILSE MUCHITSCH, CHRISTINE MAROSI, MICHAEL SCHUMACHER, SABINE ZÖCHBAUER-MÜLLER, RAJ K. MANCHANDA, ANDREA SCHROTT, OTTO BURGHUBER

*The Oncologist* 2020;25:e1930–e1955; first published on November 7, 2020; doi: 10.1002/onco.13548

In the Additional Details of Endpoints or Study Design section of this report, it was reported that “Eight of the randomized patients had to be excluded because of sensitizing *EGFR* mutations or *ALK* translocations reported immediately after randomization (four in the homeopathy group, four in the control group).” In the parenthetical note, “control group” should have been “placebo group”. This error does not affect the results of this study, but in the interest of clarity, the online version of this article has been corrected.